Identity
- Security key
- 14336
- Ticker
- DNTH
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2023-09-12
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- DNTH
Detail
Enriched 2026-08-14 20:47
- Market cap
- $6,287,583,430.98
- Shares outstanding (class)
- 54,666,233
- Shares outstanding (weighted)
- 55,934,378
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 92
- Location
- NEW YORK, NY
- Homepage
- https://www.dianthustx.com
- Description
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Market cap and share counts drift.